Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Down 85.5% in August

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a significant decline in short interest in August. As of August 14th, there was short interest totaling 29,679 shares, a decline of 85.5% from the July 30th total of 205,218 shares. Approximately 6.3% of the company’s stock are short sold. Based on an average trading volume of 85,940 shares, the short-interest ratio is presently 0.3 days.

Jupiter Neurosciences Stock Down 14.5%

Shares of JUNS stock traded down $0.71 during trading on Friday, reaching $4.18. The company had a trading volume of 226,951 shares, compared to its average volume of 2,744,316. The firm’s 50 day simple moving average is $10.45 and its two-hundred day simple moving average is $22.30. Jupiter Neurosciences has a one year low of $4.10 and a one year high of $137.96.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its earnings results on Friday, August 14th. The company reported ($5.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.40 million.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JUNS. Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a report on Sunday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Jupiter Neurosciences currently has a consensus rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Vestor Capital LLC grew its stake in Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after buying an additional 970,314 shares during the last quarter. Yorkville Advisors Global LP bought a new position in Jupiter Neurosciences in the 4th quarter worth $135,000. Allen Capital Group LLC acquired a new position in Jupiter Neurosciences during the 4th quarter worth $31,000. Finally, Geode Capital Management LLC lifted its position in Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after acquiring an additional 28,826 shares during the last quarter.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.